William Blair Predicts Hologic’s Q2 Earnings (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at William Blair cut their Q2 2025 earnings per share estimates for shares of Hologic in a research report issued to clients and investors on Thursday, February 6th. William Blair analyst A. Brackmann now expects that the medical equipment provider will post earnings of $1.00 per share for the quarter, down from their previous estimate of $1.07. William Blair has a “Outperform” rating on the stock. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share.

A number of other brokerages have also weighed in on HOLX. Wolfe Research assumed coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating for the company. UBS Group lifted their target price on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Jefferies Financial Group initiated coverage on Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target on the stock. Finally, Royal Bank of Canada dropped their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $85.77.

Hologic Trading Up 1.0 %

HOLX opened at $65.24 on Monday. Hologic has a 1-year low of $63.62 and a 1-year high of $84.67. The firm has a 50-day moving average price of $72.06 and a two-hundred day moving average price of $77.67. The stock has a market capitalization of $14.73 billion, a PE ratio of 20.58, a PEG ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%.

Institutional Investors Weigh In On Hologic

Large investors have recently modified their holdings of the business. Prentiss Smith & Co. Inc. grew its stake in Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after buying an additional 130 shares in the last quarter. Covestor Ltd grew its position in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares in the last quarter. First Horizon Advisors Inc. increased its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 134 shares during the last quarter. Brooklyn Investment Group raised its position in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares in the last quarter. Finally, Empirical Finance LLC lifted its stake in Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 147 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.